ALXO.US Alx Oncology Holdings 

Healthcare Biotechnology USA Stocks
1.04 USD
Close of Nov 14, 2026
0.8617 2.66
Market cap
USD 144M
P/E
-
P/B
1.10x
ROE
-52.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ALXO.US undervalued?

Graham number

The Graham number of Alx Oncology Holdings  cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alx Oncology Holdings  fundamental analysis

No fundamental analysis for Alx Oncology Holdings  yet.

Alx Oncology Holdings  stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alx Oncology Holdings 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceutica…

Full company profile